BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 246 filers reported holding BIO-TECHNE CORP in Q1 2015. The put-call ratio across all filers is - and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2021 | $810,000 | -57.6% | 1,800 | -64.0% | 0.01% | -57.9% |
Q1 2021 | $1,910,000 | +25.3% | 5,000 | +4.2% | 0.02% | +18.8% |
Q4 2020 | $1,524,000 | +28.2% | 4,800 | 0.0% | 0.02% | +14.3% |
Q3 2020 | $1,189,000 | -16.6% | 4,800 | -11.1% | 0.01% | -17.6% |
Q2 2020 | $1,426,000 | +53.5% | 5,400 | +10.2% | 0.02% | +30.8% |
Q1 2020 | $929,000 | -40.4% | 4,900 | -31.0% | 0.01% | -23.5% |
Q4 2019 | $1,559,000 | +44.9% | 7,100 | +29.1% | 0.02% | +41.7% |
Q3 2019 | $1,076,000 | -2.6% | 5,500 | +3.8% | 0.01% | -7.7% |
Q2 2019 | $1,105,000 | -33.8% | 5,300 | -36.9% | 0.01% | -35.0% |
Q1 2019 | $1,668,000 | +0.2% | 8,400 | -27.0% | 0.02% | -9.1% |
Q4 2018 | $1,664,000 | -29.7% | 11,500 | -0.9% | 0.02% | -18.5% |
Q3 2018 | $2,368,000 | +86.2% | 11,600 | +34.9% | 0.03% | +68.8% |
Q2 2018 | $1,272,000 | +266.6% | 8,600 | +273.9% | 0.02% | +300.0% |
Q1 2018 | $347,000 | -81.8% | 2,300 | -84.4% | 0.00% | -81.8% |
Q4 2017 | $1,904,000 | -13.9% | 14,700 | -19.7% | 0.02% | -18.5% |
Q3 2017 | $2,212,000 | -14.0% | 18,300 | -16.4% | 0.03% | -15.6% |
Q2 2017 | $2,573,000 | +56.2% | 21,900 | +35.2% | 0.03% | +52.4% |
Q1 2017 | $1,647,000 | +45.6% | 16,200 | +47.3% | 0.02% | +31.2% |
Q4 2016 | $1,131,000 | -9.4% | 11,000 | -3.5% | 0.02% | -11.1% |
Q3 2016 | $1,248,000 | +163.3% | 11,400 | +171.4% | 0.02% | +157.1% |
Q2 2016 | $474,000 | -29.3% | 4,200 | -38.2% | 0.01% | -30.0% |
Q2 2015 | $670,000 | -55.2% | 6,800 | -54.4% | 0.01% | -56.5% |
Q1 2015 | $1,494,000 | +8.5% | 14,900 | 0.0% | 0.02% | +9.5% |
Q4 2014 | $1,377,000 | – | 14,900 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Blue Water Life Science Advisors, LP | 54,711 | $28,304,000 | 8.66% |
Montanaro Asset Management Ltd | 104,450 | $54,036,000 | 5.45% |
Ownership Capital B.V. | 891,186 | $461,046,000 | 4.99% |
Sandhill Capital Partners LLC | 121,682 | $62,951,000 | 4.89% |
Brown Capital Management | 986,803 | $510,513,000 | 4.22% |
STONE RUN CAPITAL, LLC | 22,300 | $11,536,000 | 3.73% |
DF DENT & CO INC | 681,416 | $352,524,000 | 3.54% |
MAIRS & POWER INC | 653,815 | $338,244,000 | 3.13% |
Summit Creek Advisors LLC | 57,959 | $29,985,000 | 3.01% |
Aristotle Atlantic Partners, LLC | 95,597 | $49,456,000 | 2.87% |